May, 2025
May 2025
M T W T F S S
 1234
567891011
12131415161718
19202122232425
262728293031  
Matthew Goetz: Endocrine Therapy Omission in Estrogen Receptor–Low Early-Stage Breast Cancer
Apr 13, 2025, 06:09

Matthew Goetz: Endocrine Therapy Omission in Estrogen Receptor–Low Early-Stage Breast Cancer

Matthew Goetz, Professor of Oncology and Pharmacology at Mayo Clinic, shared on LinkedIn:

“There is great controversy regarding the benefit of endocrine therapy (ET) in estrogen receptor (ER) low (1-10%) breast cancer.

Our data published online today demonstrates that ET omission in ER low breast cancer is associated with significantly higher rates of death, especially in patients with residual disease following neoadjuvant chemotherapy (NAC) and those with higher ER (6-10%) levels. Physicians should retest the residual tumor following NAC for ER and recommend ET for ER+ tumors.”

“Endocrine Therapy Omission in Estrogen Receptor–Low (1%-10%) Early-Stage Breast Cancer.”

Authors: Grace M. Choong, Tanya L. Hoskin, Judy C. Boughey, James N. Ingle, Matthew P. Goetz

Matthew Goetz: Endocrine Therapy Omission in Estrogen Receptor–Low Early-Stage Breast Cancer